Sökning: WFRF:(Kunz Pamela L.) >
Telotristat Ethyl, ...
-
Kulke, Matthew H.Dana Farber Canc Inst, Boston, MA 02115 USA.
(författare)
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
- Artikel/kapitelEngelska2017
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-315064
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-315064URI
-
https://doi.org/10.1200/JCO.2016.69.2780DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated telotristat ethyl in this setting. Patients and Methods Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1: 1: 1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment period. The primary end point was change from baseline in BM frequency. In an open-label extension, 115 patients subsequently received telotristat ethyl 500 mg. Results Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were -0.81 for telotristat ethyl 250 mg (P < .001) and -0.69 for telotristat ethyl 500 mg (P,.001). At week 12, mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg were -0.9, -1.7, and -2.1, respectively. Responses, predefined as a BM frequency reduction >= 30% from baseline for >= 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of patients given placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg, respectively. Both telotristat ethyl dosages significantly reduced mean urinary 5-hydroxyindole acetic acid versus placebo at week 12 (P < .001). Mild nausea and asymptomatic increases in gamma-glutamyl transferase were observed in some patients receiving telotristat ethyl. Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment. Conclusion Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in BM frequency and urinary 5-hydroxyindole acetic acid.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Hoersch, DieterZentralklinik Bad Berka, Bad Berka, Germany.
(författare)
-
Caplin, Martyn E.Royal Free Hosp, London, England.
(författare)
-
Anthony, Lowell B.Univ Kentucky, Lexington, KY USA.
(författare)
-
Bergsland, EmilyUniv Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
(författare)
-
Öberg, KjellUppsala universitet,Endokrin tumörbiologi(Swepub:uu)kjellob
(författare)
-
Welin, StaffanUppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)stafweli
(författare)
-
Warner, Richard R. P.Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
(författare)
-
Lombard-Bohas, CatherineHosp Civils Lyon, Hop Edouard Herriot, Lyon, France.
(författare)
-
Kunz, Pamela L.Stanford Univ, Palo Alto, CA 94304 USA.
(författare)
-
Grande, EnriqueHosp Univ Ramon y Cajal, Madrid, Spain.
(författare)
-
Valle, Juan W.Univ Manchester, Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England.
(författare)
-
Fleming, DouglasIpsen Biosci, Cambridge, MA USA.
(författare)
-
Lapuerta, PabloLexicon Pharmaceut, The Woodlands, TX USA.
(författare)
-
Banks, PhillipLexicon Pharmaceut, The Woodlands, TX USA.
(författare)
-
Jackson, ShannaLexicon Pharmaceut, The Woodlands, TX USA.
(författare)
-
Zambrowicz, BrianLexicon Pharmaceut, The Woodlands, TX USA.
(författare)
-
Sands, Arthur T.Lexicon Pharmaceut, The Woodlands, TX USA.
(författare)
-
Pavel, MarianneCharite, Berlin, Germany.
(författare)
-
Dana Farber Canc Inst, Boston, MA 02115 USA.Zentralklinik Bad Berka, Bad Berka, Germany.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Clinical Oncology35:1, s. 14-230732-183X1527-7755
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kulke, Matthew H ...
-
Hoersch, Dieter
-
Caplin, Martyn E ...
-
Anthony, Lowell ...
-
Bergsland, Emily
-
Öberg, Kjell
-
visa fler...
-
Welin, Staffan
-
Warner, Richard ...
-
Lombard-Bohas, C ...
-
Kunz, Pamela L.
-
Grande, Enrique
-
Valle, Juan W.
-
Fleming, Douglas
-
Lapuerta, Pablo
-
Banks, Phillip
-
Jackson, Shanna
-
Zambrowicz, Bria ...
-
Sands, Arthur T.
-
Pavel, Marianne
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Uppsala universitet